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As statins are recommended at discharge to all patients
following myocardial infarction (MI), we studied their use and
efficacy in renal disease by analyzing the data, in the
nationwide SWEDEHEART registry, of 42,814 consecutive
survivors of MI with available creatinine/dialysis data but
without statin therapy on admission. The estimated
glomerular filtration rate (eGFR) was determined by the
Modification of Diet in Renal Disease Study formula and the
patients classified into the five traditional stages of kidney
disease. The 1-year survival in relation to prescription of
statin at discharge was assessed in a Cox regression analysis
adjusted by a propensity score that described each
individual’s likelihood of being treated with a statin,
established by 36 baseline characteristics and in-hospital
therapies. Statin use at discharge decreased with increased
renal impairment from 81% in eGFR stage 1 to 31% in eGFR
stage 5. After adjusting for the propensity score and
discharge medication, statin use was associated with a
significant reduction in overall risk of death (hazard ratio
0.63), with a statistically significant interaction between statin
therapy and the stage of renal function. Thus, statin use at
discharge was associated with improved 1-year survival of
patients in stages 2–4 (mild-to-severe) of renal insufficiency.
This effect appears attenuated in those with stage 5 renal
failure.
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Patients with renal impairment and acute myocardial infarction
(MI) are at high risk of adverse events. The mortality increases
exponentially with worsening renal function, and is particularly
high in those receiving renal replacement therapy.1 Guidelines
uniformly recommend that patients with an acute MI be treated
with statin to reduce their risk of subsequent cardiovascular events,
including revascularization, recurrent MI, stroke, and death.
The benefit with statin therapy in MI patients extends to
patients with mild-to-moderate renal insufficiency in post hoc
analyses of randomized trials.2–4 Despite this evidence in
favor of therapy, several observational analyses indicate that
statins are prescribed less frequently to those with renal
impairment.5–7 Less is known about the effect of statin in
those with severe renal insufficiency or dialysis following a
MI, although statin therapy has not been shown to alter the
outcome in randomized trials assessing its effect in primary
prevention in hemodialysis patients.8,9
The aim of this study was to examine the current use of
statins and the association between statin prescription at
discharge and mortality at different degrees of renal
dysfunction. For this purpose, we used the data pertaining
to in-hospital survivors of a broad unselected MI population
entered into a nationwide register in Sweden between 2003
and 2006, who were not prescribed statin on admission.
RESULTS
A total of 42,814 in-hospital MI survivors, without statin
therapy on admission, were classified according to their
estimated glomerular filtration rate (eGFR) into five renal
function stages. The median eGFR excluding dialysis patients
was 73ml/min per 1.73m2 (interquartile range (IQR) 57–89).
A minority (n¼ 178 patients) received dialysis for a median
of 24 months (IQR 11–59) before admission. With lower
renal function, patients were older, had more cardiovascular
comorbidities such as diabetes and hypertension, and had
more frequently been revascularized before the index event
(Table 1).
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Table 1 | Baseline characteristics
eGFR (ml/min per 1.73m2)
All
(n=42,814)
eGFR X90
(n=9935)
eGFR 60–89
(n=20,135)
eGFR 30–59
(n=11,103)
eGFR 15–29
(n=1273)
eGFR o15/dialysis
(n=368)
Age, mean±s.d. 70.8±12.6 62.9±12.2 69.8±11.7 78.5±9.4 81.0±9.0 72.9±12.6
Male 63.3 (27,111) 74.8 (7433) 66.7 (13,422) 48.7 (5408) 47.6 (606) 65.8 (242)
Diabetes 17.3 (7399) 14.6 (1449) 14.7 (2957) 22.0 (2441) 32.3 (411) 38.3 (141)
Hypertension 37.4 (15,773) 28.0 (2748) 34.8 (6924) 47.8 (5207) 55.9 (698) 55.4 (195)
Previous myocardial infarction 13.9 (5949) 7.8 (771) 10.6 (2141) 22.5 (2500) 33.2 (422) 31.0 (114)
Previous CHF 10.7 (4580) 3.3 (327) 6.3 (1278) 20.9 (2326) 40.7 (518) 35.6 (131)
Previous PCI 2.1 (910) 1.8 (181) 2.0 (409) 2.4 (259) 3.1 (39) 6.1 (22)
Previous CABG 3.5 (1496) 2.4 (234) 3.0 (610) 4.9 (543) 7.0 (88) 5.8 (21)
Previous COPD 5.4 (2330) 4.1 (406) 4.5 (909) 7.7 (857) 9.8 (125) 9.0 (33)
Previous stroke 8.8 (3776) 4.4 (442) 7.0 (1402) 14.7 (1627) 18.3 (233) 19.6 (72)
Previous PVD 3.8 (1643) 1.9 (190) 2.6 (531) 6.4 (706) 12.3 (156) 16.3 (60)
Known dementia 0.3 (122) 0.2 (18) 0.3 (54) 0.4 (42) 0.6 (8) 0.0 (0)
Cancer diagnosis within last 3 years 3.3 (1412) 2.4 (240) 2.8 (572) 4.5 (504) 5.3 (67) 7.9 (29)
Admission ECG
STEMI/LBBB 43.2 (18,020) 46.4 (4507) 43.8 (8623) 40.3 (4330) 36.3 (444) 32.9 (116)
NSTEMI 56.8 (23,707) 53.6 (5209) 56.2 (11,073) 59.7 (6409) 63.7 (779) 67.1 (237)
Medication on admission
Aspirin/clopidogrel 29.9 (12,762) 18.2 (1804) 26.3 (5281) 43.5 (4823) 52.7 (670) 50.1 (184)
Warfarin 3.8 (1624) 2.2 (214) 3.0 (605) 6.2 (684) 8.3 (105) 4.4 (16)
b-Blocker 28.8 (12,300) 18.5 (1832) 25.8 (5180) 40.0 (4428) 51.7 (658) 55.5 (202)
Other lipid lowering 0.6 (242) 0.5 (50) 0.5 (103) 0.6 (71) 0.7 (9) 2.4 (9)
Antidiabetic (po/insulin) 12.1 (960) 9.7 (960) 10.1 (2039) 16.1 (1788) 23.7 (302) 25.0 (92)
ACE/ARB inhibitor 18.4 (7886) 11.9 (1178) 15.4 (3094) 27.5 (3044) 35.3 (450) 32.7 (120)
Nitroglycerine 10.1 (4313) 4.5 (449) 7.8 (1560) 17.0 (1888) 26.3 (334) 22.6 (83)
Diuretic 23.9 (10,207) 10.0 (997) 17.4 (3492) 42.0 (4656) 66.2 (843) 59.7 (219)
Calcium antagonist 13.1 (5593) 9.3 (922) 11.9 (2393) 16.9 (1869) 23.5 (298) 30.6 (111)
Digoxin 4.3 (1853) 2.0 (195) 3.2 (647) 7.9 (872) 9.3 (118) 5.7 (21)
In-hospital complication
Heart failure 31.8 (13,565) 18.1 (1799) 26.2 (5254) 49.2 (5445) 69.3 (878) 52.2 (189)
In-hospital therapies
Reperfusion therapy 30.5 (12,853) 38.4 (3764) 33.3 (6589) 21.2 (2319) 11.7 (148) 9.3 (33)
Revascularization 45.9 (19,668) 61.8 (6140) 50.9 (10,253) 27.7 (3070) 12.0 (153) 14.1 (52)
Only coronary angiography 15.0 (6432) 17.3 (1722) 16.7 (3361) 11.5 (1271) 4.1 (52) 7.1 (26)
Sc LMWH/iv heparin 73.4 (31,176) 72.7 (7177) 74.6 (14,899) 72.8 (8023) 67.1 (849) 63.5 (228)
Iv b-blocker 34.7 (14,732) 37.6 (3718) 35.5 (7093) 31.6 (3480) 26.5 (333) 29.9 (108)
Iv nitroglycerine 20.0 (8475) 18.3 (1801) 20.2 (4034) 21.1 (2318) 19.3 (243) 22.0 (79)
Iv inotrope 2.5 (1063) 1.7 (167) 2.0 (396) 3.7 (409) 6.3 (79) 3.3 (12)
Iv diuretic 27.2 (11,534) 14.7 (1450) 21.9 (4378) 43.3 (4769) 61.7 (778) 44.3 (159)
Iv Gp2b/3a inhibitor 24.8 (10,520) 35.1 (3464) 27.0 (5396) 14.2 (1565) 6.4 (81) 3.9 (14)
Discharge medication
Aspirin/clopidogrel 93.1 (39,838) 96.2 (9556) 94.9 (19,097) 88.8 (9850) 81.4 (1035) 81.5 (300)
Warfarin 6.0 (2552) 4.0 (394) 5.4 (1092) 8.4 (930) 9.1 (116) 5.4 (20)
Long-acting nitroglycerine 17.7 (7571) 10.2 (1009) 15.5 (3110) 26.0 (2886) 34.8 (442) 33.8 (124)
ACE inhibitor/ARB 55.7 (23,787) 55.5 (5504) 56.7 (11,384) 56.7 (6290) 37.9 (482) 34.5 (127)
Calcium antagonist 11.0 (4681) 8.1 (803) 10.0 (2005) 13.8 (1525) 18.8 (239) 30.0 (109)
Digoxin 5.2 (2231) 2.6 (261) 4.1 (825) 9.1 (1013) 9.1 (116) 4.4 (16)
Diuretic 35.7 (15,248) 17.8 (1755) 28.9 (5813) 57.8 (6411) 80.0 (1017) 68.5 (252)
Antidiabetic 13.5 (5791) 11.6 (1153) 11.3 (2280) 17.6 (1951) 24.9 (317) 24.5 (90)
Type of hospital
PCI available 55.6 (23,804) 60.5 (6016) 55.5 (11,166) 51.8 (5751) 51.0 (649) 60.3 (222)
University hospital 29.4 (12,574) 32.4 (3216) 28.7 (5782) 27.7 (3081) 27.6 (351) 39.1 (144)
Year of admission
2003 23.0 (9851) 16.2 (1613) 23.3 (4683) 27.5 (3055) 28.0 (356) 39.1 (144)
2004 25.6 (10,957) 23.8 (2360) 26.0 (5232) 26.6 (2956) 26.9 (343) 17.9 (66)
2005 25.9 (11,081) 28.8 (2858) 25.6 (5150) 24.3 (2698) 23.0 (293) 22.3 (82)
2006 25.5 (10,925) 31.2 (3104) 25.2 (5070) 21.6 (2394) 22.1 (281) 20.7 (76)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; Gp2b/3a, glycoprotein 2b/3a; Iv, intravenous; LBBB, left bundle branch block; LMWH, low-molecular weight heparin; NSTEMI,
non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; Sc, subcutaneous; STEMI, ST-elevation myocardial infarction.
Percentage % (n) or mean±s.d.
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A majority of patients (67.2%) received a statin at
discharge. With lower renal function, the proportion of
patients receiving a statin decreased (Figure 1a). During the
study period between 2003 and 2006, an increasing number
of patients were prescribed a statin (Figure 1b). Patients with
statin differed from those without by being younger, some
having diabetes, hypertension, previous MI, or heart failure,
and some having cardioprotective medication on admission
(Table 2). After standardizing according to the propensity
score distribution in patients without statin, the distribution
of baseline characteristics appeared to be comparable by
visual inspection and by having a low standardized
difference.
About a third of patients (34.2%) did not have cholesterol
level reported. Fewer patients without a statin at discharge
had cholesterol registered (46.5 versus 75.3%, Po0.001)
(Table 3). Patients who received a statin had higher median
low-density lipoprotein (LDL) cholesterol on admission
compared with those without a statin (3.3 (IQR 2.2–4.0)
versus 2.6mmol/l (IQR 2.1–3.2), Po0.001), and more
patients had an LDL cholesterol 42.5mmol/l (81.8 versus
56.4%, Po0.001).
Mortality at 1 year increased with lower renal function in
patients with and without statin (Figure 2). The unadjusted
mortality among those without statin was higher than that
for patients with statin (23.9 versus 5.0%, Po0.001). After
adjusting for propensity score and discharge medication,
statin use was associated with a 37% reduced overall risk of
death (hazards ratio 0.63, 95% confidence interval 0.58–0.68,
Po0.001). After adjustment, there was a statistically
significant interaction between statin therapy and renal
function stage (Po0.001). Although the effect of statin
therapy on survival appeared to decline with lower renal
function, statin therapy was still associated with a lower
mortality in all renal function stages, except in those with
renal failure (Figure 3).
There was no major change in the point estimates for the
association between statin use and mortality in the Cox
proportional hazards model when eGFR was used as a
continuous variable in the propensity score (Supplement S1
online). When the analyses were limited to patients with
available LDL level and adjusted for it, the results were
similar, except for a remaining uncertainty of the effect of
statins in patients with more advanced renal dysfunction on
mortality (Supplement S2 online). In a sensitivity analysis
including all patients with missing covariates, the results
remained similar (Supplement S3 online). The distribution of
patients with missing outcome data (n¼ 196) was similar across
the renal function groups (P¼ 0.626). There was no difference
in the main result if the patients with missing outcome data
were included in the propensity score (data not shown).
DISCUSSION
In this current nationwide study of unselected MI patients
without a statin on admission, prescription of statin at
discharge declined with lower renal function. After adjust-
ment for confounders, statin use at discharge was associated
with lower all-cause mortality at 1 year in all renal function
stages, except in patients with renal failure.
Subanalyses from randomized statin trials have shown
a 23–32% relative reduction of cardiovascular events in
those with mild-to-moderate renal insufficiency and
either known coronary heart disease or recent MI.2–4 The
data in those with more advanced renal insufficiency
have been limited. Previous subanalyses of the CARE
trial showed that patients with mild renal insufficiency
(creatinine clearance p75ml/min) and an MI 3–20 months
before randomization had a 28% reduction of cardiovascular
events with pravastatin.4 However, patients with creatinine
more than 1.5 times above the upper limit of normal
were excluded. The Pravastatin Pooling Project3 showed that
patients with moderate renal insufficiency (mean eGFR
55ml/min per 1.73m2) with either an MI or at high risk
treated with pravastatin had a 23% reduction in cardio-
vascular events. Similarly, in a subanalysis of the Treating to
New Targets study,2 patients with coronary heart disease and
moderate renal insufficiency (mean 53ml/min per 1.73m2)
had a 32% reduction of cardiovascular risk with high-dose
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Figure 1 | Statin use at discharge. (a) Statin use at discharge in
myocardial infarction hospital survivors admitted without a statin.
(b) Statin use at discharge according to treatment year. eGFR,
estimated glomerular filtration rate.
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Table 2 | Baseline characteristics for patients with and without statin at discharge
With statin
(n=26,753)
No statin
(n=12,772)
Standardized
(no statin=standard)
Standardized
difference
Age, mean±s.d. 67.1±11.7 78.2±11.1 78.5±9.3 12.1
Male 67.9 54.3 55.6 6.2
Diabetes 15.0 21.4 23.1 1.1
Hypertension 35.4 41.1 42.5 0.7
Previous myocardial infarction 8.9 22.8 22.3 2.5
Previous congestive heart failure 5.1 21.4 18.7 3.2
Previous PCI 1.8 2.5 3.2 0.3
Previous CABG 2.8 4.6 5.2 0.7
Previous COPD 3.9 8.5 8.8 1.3
Previous stroke 5.5 15.2 14.5 2.1
Previous PVD 2.7 6.1 6.3 1.1
Known dementia 0.1 0.6 0.0 0.2
Cancer diagnosis 2.5 5.0 5.0 0.9
Admission ECG
STEMI/LBBB 45.6 37.1 63.1 0.8
Medication on admission
Aspirin/clopidogrel 22.5 44.1 44.8 2.6
Warfarin 2.6 6.0 5.8 1.2
b-Blocker 24.0 37.8 39.1 1.8
Other lipid lowering 0.5 0.5 0.9 0.0
ACE/ARB inhibitor 15.8 23.8 24.8 1.3
Nitroglycerine 6.1 17.6 18.1 2.3
Diuretic 15.8 39.5 36.8 3.2
Calcium antagonist 11.6 16.3 17.5 0.9
Digoxin 2.1 8.6 7.2 2.0
In-hospital complication
Heart failure 23.0 48.6 46.2 3.0
In-hospital therapies
Reperfusion therapy 37.7 16.0 17.9 3.0
Revascularization 60.2 18.7 20.8 4.7
Only coronary angiography 18.2 9.4 11.0 1.7
Sc LMWH/Iv heparin 75.4 69.2 74.7 0.5
Iv b-blocker 37.3 29.3 30.9 1.0
Iv nitroglycerine 20.6 18.5 3.6 0.6
Iv inotrope 2.0 3.3 19.9 0.3
Iv diuretic 19.3 42.2 40.0 2.9
Iv Gp2b/3a inhibitor 32.6 8.8 9.8 3.7
Discharge medication
Aspirin/clopidogrel 96.9 85.2 92.8 0.9
Warfarin 5.0 7.7 9.0 0.8
Long-acting nitroglycerine 12.7 27.3 29.1 2.3
ACE inhibitor/ARB 61.0 45.4 62.1 1.5
Calcium antagonist 9.4 13.9 13.7 0.9
Digoxin 2.7 10.2 7.0 2.1
Diuretic 25.1 56.1 52.3 3.4
Antidiabetic 12.1 16.1 18.2 0.8
Type of hospital
PCI available 57.9 48.5 48.8 0.9
University hospital 31.1 23.8 24.6 1.0
Year of admission
2003 19.8 28.9 24.6 1.3
2004 24.7 26.7 28.6 0.3
2005 27.0 24.2 27.0 0.4
2006 28.5 20.3 24.4 1.2
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease;
Gp2b/3a, glycoprotein 2b/3a; Iv, intravenous; LBBB, left bundle branch block; LMWH, low-molecular weight heparin; PCI, percutaneous coronary intervention; PVD, peripheral
vascular disease; Sc, subcutaneous; STEMI, ST-elevation myocardial infarction.
Reported as percentage % or as indicated.
Patient group without statin is the standard for propensity score distribution (n=39,525).
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atorvastatin compared with a low dose. This registry
confirms the benefit of statin in those with a recent MI and
a moderate renal insufficiency, and extends the evidence to
include those with severely reduced renal function. Although
the association between statin treatment and mortality
weakened with declining renal function, these data strongly
suggest that patients with moderate and severe renal
insufficiency benefit from statins after a MI.
Patients with mild or moderate renal insufficiency
received therapy with statin less frequently than patients
with normal renal function in this study. Renal impairment is
by itself a predictor of lower statin use at discharge.5
Cholesterol level was registered in only 67% of patients,
and there was a differential reporting with fewer measure-
ments in patients with lower renal function. Therefore, no
firm conclusion can be made whether cholesterol level in
those with lower renal function influenced statin treatment,
although other studies indicate that a less frequent use of
statin cannot be explained by less hypercholesterolemia or
better control of LDL cholesterol level.7 Statin therapy has
been shown to be both safe and efficient in lowering
cholesterol levels, with a comparable effect to that in patients
with normal renal function.10
Statin therapy in patients with renal failure was not
associated with better survival. As the patient numbers in this
group were small, only large differences in mortality between
patients with and without statin could have been detected.
The lack of effect is most likely not explained by the short
duration of given therapy, as myocardial ischemia can be
expected to be reduced early and to have an effect on
mortality already at 1 year after the acute event.11,12 Patients
with renal failure may not have cardiovascular events that are
preventable by the use of a statin. In the dialysis population,
only half of the deaths are cardiac,1 and the majority of these
are sudden deaths.6,13
Studies testing statins for primary prevention in hemo-
dialysis patients have not found an effect on cardiovascular
events. A low cholesterol level has been associated with a
worse prognosis in hemodialysis patients.14 This may imply
different mechanisms and a ‘reverse causality’, although when
confounders such as malnutrition and inflammation are
accounted for, the same relationship is present in hemodia-
lysis as in other patients.15 Only one observation study, which
may be subject to selection bias, has found an overall
improvement in both cardiovascular and all-cause mortality
in hemodialysis patients.16 Two randomized trials in
hemodialysis patients have, despite doses that substantially
Table 3 | Cholesterol values (mmol/l) on admission
eGFR (ml/min per 1.73m2) eGFR X90 eGFR 60–89 eGFR 30–59 eGFR 15–29 eGFR o15/dialysis P
With statin at discharge
Total cholesterol reported, % (n) 86.5% (6976) 85.0% (12,559) 78.5% (4266) 69.4% (254) 56.6% (64) o0.001
Cholesterol, median (IQR) 5.2 (4.6–6.0) 5.3 (4.7–6.1) 5.3 (4.6–6.1) 5.4 (4.6–6.3) 4.6 (3.7–5.8) o0.001
LDL reported, % (n) 76.7% (6193) 76.9% (11,361) 70.4% (3826) 61.7% (226) 44.2% (50) o0.001
LDL, median (IQR) 3.3 (2.7–4.0) 3.4 (2.8–4.0) 3.3 (2.6–4.0) 3.4 (2.5–4.1) 3.0 (2.2–3.6) o0.001
LDL42.5, % (n) 81.2% (5024) 83.1% (9447) 70.1% (3026) 76.1% (172) 70.0% (35) o0.001
Triglycerides reported, % (n) 82.7% (6676) 81.8% (12,091) 75.3% (4095) 66.4% (243) 53.1% (60) o0.001
Triglycerides, median (IQR) 1.5 (1.1–2.1) 1.4 (1.1–2.0) 1.4 (1.1–2.0) 1.7 (1.2–2.3) 1.6 (1.2–2.2) o0.001
HDL reported, % (n) 79.8% (6441) 79.5% (11,740) 72.6% (3948) 65.3% (239) 46.0% (52) o0.001
HDL, median (IQR) 1.2 (1.0–1.4) 1.2 (1.0–1.5) 1.2 (1.0–1.5) 1.1 (0.9–1.4) 1.1 (0.9–1.3) o0.001
Without statin at discharge
Total cholesterol reported, % (n) 62.2% (1158) 57.6% (3085) 44.7% (2532) 40.2% (365) 36.5% (93) o0.001
Cholesterol, median (IQR) 4.4 (3.9–5.0) 4.5 (4.0–5.2) 4.6 (3.9–5.3) 4.4 (3.7–5.4) 4.5 (3.9–5.2) o0.001
LDL reported, % (n) 55.4% (1033) 52.3% (2801) 40.3% (2285) 36.3% (329) 31.4% (80) o0.001
LDL, median (IQR) 2.5 (2.1–3.0) 2.6 (2.2–3.2) 2.7 (2.1–3.3) 2.5 (1.9–3.3) 2.8 (2.1–3.3) o0.001
LDL42.5, % (n) 51.1% (528) 57.4% (1606) 58.7% (1341) 48.9% (161) 61.2% (49) o0.001
Triglycerides reported, % (n) 58.9% (1097) 55.4% (2970) 42.6% (2416) 38.4% (348) 34.1% (87) o0.001
Triglycerides, median (IQR) 1.2 (0.9–1.7) 1.2 (0.9–1.7) 1.3 (1.0–1.7) 1.4 (1.1–1.9) 1.6 (1.0–2.2) o0.001
HDL reported, % (n) 55.6% (1054) 53.5% (2866) 41.3% (2340) 37.0% (336) 32.5% (83) o0.001
HDL, median (IQR) 1.2 (1.0–1.5) 1.2 (1.0–1.5) 1.2 (1.0–1.5) 1.1 (0.9–1.4) 1.1 (1.0–1.4) o0.001
Abbreviations: eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein.
LDL calculated by Friedwald’s formula (only if triglycerides p4.5mmol/l): total cholesterolHDL0.45 triglycerides.
To convert mmol/l to mg/dl, multiply cholesterol, LDL and HDL with 38.7, and triglycerides with 88.6.
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Figure 2 |Kaplan–Meier curve for 1-year mortality.
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reduce the total cholesterol and LDL level, not been able to
show a reduction of cardiovascular events in primary
prevention.8,9 However, only 10–18% of the patients included
in these trials had a prior MI. It is possible that statin therapy
is associated with other adverse events in patients with severe
renal dysfunction that physicians have to be cautious about.
In the 4D (German Diabetes and Dialysis) Study,9 which
included diabetic patients receiving statin, there was an
increase in the number of fatal strokes in the statin-treated
group. However, this result could not be confirmed in the
AURORA study,8 except for an increase in hemorrhagic
strokes in the diabetic subgroup receiving hemodialysis. If
there were fatal events caused by statins in hemodialysis
patients, this would have decreased the benefit for this group.
There are limitations. This is an observational analysis,
and, despite adjustment for confounders, selection bias may
overestimate the benefit with therapy, as factors related to
both better prognosis and therapy may not have been
included. As this is not a randomized trial, the precise effect
with statin therapy may not be estimated accurately, although
analyses across renal function stages suggest a benefit in all
but the lowest renal function group. Other limitations
include the lack of data regarding treatment doses, type of
statin used, and the number of ‘crossovers’, with patients
changing treatment during follow-up. Only statin-naive
patients were included to study the effect of new statin
therapy on subsequent outcome following a MI. Patients with
other indications for statin therapy were not included. In
addition to cardiac death, statins also reduce the risk of
stroke, revascularization, and recurrent MI. By only analyzing
mortality, this study may have underestimated any other
associated benefit, which may have contributed to the lack of
effect in patients with renal failure.
In conclusion, fewer patients with renal dysfunction
receive recommended statin therapy at discharge, although
statins have substantial benefit in preventing poor
outcome in patients with mild-to-severe reduced renal
function. Whether patients with renal failure benefit remains
unclear.
PATIENTS AND METHODS
Patient population
Consecutive patients admitted to a coronary care unit and
entered in the nationwide Swedish Web-system for Enhance-
ment and Development of Evidence-based care in Heart
disease Evaluated According to Recommended Therapies
(SWEDEHEART) register between 2003 and 2006 were
available for analyses. All patients included in the analyses
(n¼ 42,814) were in-hospital survivors of MI, had no statin
therapy on admission, and had either available in-hospital
creatinine measurement or known dialysis status. The present
study is based on data from the part of SWEDEHEART
previously known as the Register of Information and
Knowledge about Swedish Heart Intensive care Admission
(RIKS-HIA, http://www.ucr.uu.se/rikshiaint/). The main end
point was all-cause 1-year mortality. There were 196 patients
(0.5% of all) with missing vital status that were excluded.
In 2006, the registry included all patients admitted to a
coronary care unit at 71 of 74 hospitals admitting patients with
acute coronary syndrome in Sweden. Information is collected
prospectively for more than 100 variables (see http://www.
ucr.uu.se/rikshiaint/ for details) and includes baseline char-
acteristics, electrocardiographic changes, biochemical markers,
in-hospital course, interventions, and discharge medications.
MI was diagnosed using current guidelines.17 An acute MI was
diagnosed if troponin T or I, or two successive creatine-kinase
MB values were above the 99th percentile for the reference
population within 24 h of the index clinical event, or if the
creatine-kinase MB value was twice above the decision limit.
To ensure the correctness of the data entered, a monitor
visits about 20 hospitals each year and compares registered
data with the information in the patients’ records in 30–40
randomly chosen patients for each hospital. When 3020
randomly chosen computer forms containing 187,240
variables were reviewed during this period, there was 95%
agreement between the original patient records and the
registered data (http://www.ucr.uu.se/rikshiaint/).
Data on previous stroke, dementia, congestive heart
failure, chronic obstructive pulmonary disease, and cancer
Statin better
HR (linear scale)
0.0
eGFR < 15/dialysis
eGFR 15–29
eGFR 30–59
eGFR 60–89
eGFR > = 90
No statin
n / N (% death)
102/215 (47%)
387/819 (47%)
1481/5101 (29%)
813/4846 (17%)
240/1681 (14%)
Statin
n / N (% death)
37/94 (39%)
81/330 (25%)
510/4958 (10%)
465/13636 (3.4%)
191/7517 (2.5%)
HR (95% CI)
1.13 (0.76–1.67)
0.72 (0.56–0.94)
0.67 (0.60–0.76)
0.60 (0.52–0.68)
0.53 (0.41–0.67)
p =0.542
p =0.016
p <0.001
p <0.001
p <0.001
p -value
2.01.51.00.5
Statin not better
Figure 3 |Adjusted Cox regression analysis showing the association between statin use at discharge and 1-year mortality
following a myocardial infarction at different renal function stages. CI, confidence interval; eGFR, estimated glomerular filtration rate;
HR, hazards ratio.
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were obtained from the National Patient Registry, which
collects all discharge diagnosis for patients admitted to a
hospital in Sweden. The Swedish Renal Registry provided
information on dialysis therapy. All-cause 1-year mortality
data were obtained from the National Death Registry.
All patients were informed about their participation in the
registry and the follow-up, and had the right to refuse
participation. The registry and the merging of registries were
approved by the National Board of Health and Welfare, and
the local ethics committee at Uppsala University, Sweden.
Renal function definition
Glomerular filtration rate (GFR) was estimated with the
Modification of Diet in Renal Disease Study formula,18 which
is calculated by using creatinine, age, gender, and race.
Everyone was assumed to be White. Renal function was
classified according to the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative stages:19 eGFR
490ml/min per 1.73m2 (normal), 60–90ml/min per 1.73m2
(mild), 30–59ml/min per 1.73m2 (moderate), 15–29ml/min
per 1.73m2 (severe), and o15ml/min per 1.73m2 or
receiving dialysis (renal failure). Physicians were instructed
to enter the in-hospital measurement of creatinine that best
represented the patient’s underlying renal function.
Statistical analysis
Continuous baseline characteristics are reported as mean
with standard deviation or median with IQR. Categorical
variables were analyzed using the w2-test and continuous
variables using the Kruskal–Wallis test. P-values are included
as a measure of information rather than as the result of a
formal statistical test, as this is an observational study.
Propensity score was created to express the likelihood for
receiving a statin at discharge given the baseline character-
istics, medication on admission, and received in-hospital
treatments. A logistic regression model was used to develop
the propensity score for receiving a statin at discharge and
included the following 36 clinical characteristics/medications
and hospital type: age (as a second degree polynomial),
gender, diabetes, hypertension, previous MI, heart failure,
percutaneous coronary intervention, coronary artery bypass
grafting, stroke, chronic obstructive pulmonary disease,
dementia, peripheral vascular disease, cancer diagnosis with-
in the last 3 years, medication on admission (aspirin/
thienopyridines, warfarin, b-blocker, angiotensin-converting
enzyme inhibitor/angiotensin-II receptor blocker, lipid-low-
ering drugs excluding statins, diuretic, long-acting nitrate,
digoxin, and calcium channel blocker), ST elevation/left
bundle branch block on admission ECG, intravenous
unfractionated or subcutaneous low-molecular weight he-
parin, in-hospital intravenous therapy (b-blocker, nitrate,
inotrope, diuretic, and glycoprotein 2b/3a-inhibitor), acute
reperfusion therapy, coronary angiography, in-hospital re-
vascularization (percutaneous coronary intervention/coron-
ary artery bypass grafting), signs of congestive heart failure
during hospital stay (Killip class 41, use of intravenous
diuretic or continuous positive airway pressure), university
hospital status, availability of percutaneous coronary inter-
vention at admitting hospital, and year admitted to hospital.
The balance of covariates included in the propensity score
between patients treated with and without a statin was assessed
by inspecting the standardized proportions for binary and
mean for continuous variables. The propensity score was
divided into quintiles, and the distribution from the group with
no statin was used as standard for calculating the correspond-
ing proportions and means for the statin group. The
standardized difference was calculated between the two groups.
A Cox proportional hazards model was used to assess the
adjusted association between statin and mortality at each
renal function stage. In addition to statin use at discharge, the
propensity score and nine discharge medications (aspirin
and/or thienopyridines, warfarin, b-blocker, angiotensin-
converting enzyme inhibitor/angiotensin-II receptor blocker,
diuretic, long-acting nitrate, digoxin, calcium channel
blocker, and antidiabetic) were included as covariates in the
model. Interaction between renal function stage and statin
therapy was assessed in a Cox proportional hazards model
including all patients.
As the likelihood of receiving a statin may have differed
between patients with renal impairment, a separate propen-
sity score was calculated, which, in addition to the variables
in the first model, also included eGFR as a continuous
variable. Patients who were receiving dialysis were given an
eGFR of 10ml/min per 1.73m2. The relationship between
statin use at discharge and mortality was then assessed in a
Cox proportional hazard model including the new propensity
score and the nine discharge medications (as above).
The number of patients with LDL level registered was low
(65.9%). Therefore, a separate logistic regression model that
included LDL level was used to obtain a propensity score.
This new propensity score was again used in a Cox regression
model together with discharge medication to assess the effect
of statin on 1-year mortality.
A sensitivity analysis to exclude possible bias of missing
values for the included covariates (n¼ 4977; 9.4%) was
performed. A propensity score for receiving a statin at each
renal function stage was calculated, in which the independent
dichotomous variables were coded as no, yes, or missing. The
association between statin use and outcome was then
adjusted by this new propensity score and analyzed at each
renal function stage.
Additional analyses to account for the effect of the 196
(0.5%) patients with missing outcome data were performed.
The distribution of these patients among the renal function
group was assessed with the w2 and Fisher exact tests. A new
propensity score was calculated including these patients,
which was then used in the Cox regression model together
with discharge medication to assess the effect of statin on
1-year mortality.
All analyses were performed with SPSS version 15
(Chicago, IL). The authors had full access to the data and
agree to the manuscript as written.
Kidney International (2011) 79, 997–1004 1003
K Szummer et al.: Statin, renal impairment and myocardial infarction o r ig ina l a r t i c l e
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was financially supported by the Swedish Heart and Lung
Foundation, and through a regional agreement on medical training
and clinical research (ALF) between Stockholm County Council
and Karolinska Institute. The SWEDEHEART register is supported by
the Swedish National Board of Health and Welfare, the Swedish
Association of Local Authorities, and the Swedish Society of
Cardiology.
SUPPLEMENTARY MATERIAL
Supplement 1. Adjusted association between statin use at discharge
and 1-year mortality following a MI.
Supplement 2. Effect of statin on 1-year mortality in the two-thirds
of patients with available LDL cholesterol (n¼ 26,224).
Supplement 3. Sensitivity analysis including missing covariates.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute
myocardial infarction among patients on long-term dialysis. N Engl J Med
1998; 339: 799–805.
2. Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with
atorvastatin in patients with coronary heart disease and chronic kidney
disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;
51: 1448–1454.
3. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular
events in people with chronic kidney disease. Circulation 2004; 110:
1557–1563.
4. Tonelli M, Moye L, Sacks FM et al. Pravastatin for secondary prevention of
cardiovascular events in persons with mild chronic renal insufficiency.
Ann Intern Med 2003; 138: 98–104.
5. Foody JM, Roe MT, Chen AY et al. Lipid management in patients
with unstable angina pectoris and non-ST-segment elevation acute
myocardial infarction (from CRUSADE). Am J Cardiol 2005; 95: 483–485.
6. Hage FG, Venkataraman R, Zoghbi GJ et al. The scope of coronary heart
disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;
53: 2129–2140.
7. Parikh NI, Hwang SJ, Larson MG et al. Cardiovascular disease risk factors in
chronic kidney disease: overall burden and rates of treatment and
control. Arch Intern Med 2006; 166: 1884–1891.
8. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and
cardiovascular events in patients undergoing hemodialysis. N Engl J Med
2009; 360: 1395–1407.
9. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2
diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:
238–248.
10. Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in
patients with chronic kidney disease: meta-analysis and meta-regression
of randomised controlled trials. BMJ 2008; 336: 645–651.
11. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin
on early recurrent ischemic events in acute coronary syndromes:
the MIRACL study: a randomized controlled trial. JAMA 2001; 285:
1711–1718.
12. Stenestrand U, Wallentin L. Early statin treatment following acute
myocardial infarction and 1-year survival. JAMA 2001; 285: 430–436.
13. Collins AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal
Data System 2006 Annual Data Report. Am J Kidney Dis 2007; 49: A6–A7,
S1-296.
14. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant
predictor of death in a cohort of chronic hemodialysis patients. Kidney Int
2002; 61: 1887–1893.
15. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level
and mortality in dialysis patients: role of inflammation and malnutrition.
JAMA 2004; 291: 451–459.
16. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are
associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:
297–304.
17. The joint European Society of Cardiology/American College of
Cardiology. Myocardial infarction redefined–a consensus document of
The Joint European Society of Cardiology/American College of
Cardiology Committee for the redefinition of myocardial infarction.
Eur Heart J 2000; 21: 1502–1513.
18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Intern
Med 1999; 130: 461–470.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002; 39: S1–S266.
1004 Kidney International (2011) 79, 997–1004
or ig ina l a r t i c l e K Szummer et al.: Statin, renal impairment and myocardial infarction
